CareDx, Inc. is dedicated to improving the lives of organ transplant patients through noninvasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx strives to stay at the forefront of organ transplant surveillance solutions.
AlloSure is the first and only non-invasive test that assesses organ health by directly measuring allograft injury. AlloSure can accurately determine active rejection, enabling better management of your kidney transplant patients.
AlloMap is a non-invasive blood test that helps physicians identify the risk of acute cellular rejection in heart transplant recipients.
Look for CareDx at the following 2018 events:
UNOS Transplant Management Form Meeting 2018
Austin, Texas
April 24-26, 2018
EFI 32nd Annual Meeting 2018
Venice, Italy
May 9-12, 2018
ATC 2018
Seattle, WA, United States
June 2-6, 2018
ASHI 44th Annual Meeting 2018
Baltimore, MD, United States
October 1-5, 2018